KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis.
Developing effective treatments for chronic neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) has proven extremely difficult. ALS is universally fatal, characterized by progressive weakness due to the degeneration of upper and lower motor neurons, and leads eventually to respiratory failure which is the usual cause of death. Only a single treatment has been approved, the modestly effective nonspecific neuroprotectant Rilutek (riluzole; 2-amino-6-(trifluoromethoxy)benzothiazole). KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine dihydrochloride, RPPX], a synthetic amino-benzothiazole with demonstrated activity in maintaining mitochondrial function, is being developed as a treatment for ALS. It has proven to be effective in multiple in vitro and in vivo assays of neuroprotection, including the G93A-SOD1 mutant mouse model; however, its specific mechanism of action remains unknown. The potential of KNS-760604 as a treatment for ALS was first suggested by studies showing that its optical enantiomer, Mirapex[(6S)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine; pramipexole dihydrochloride; PPX], a high-affinity agonist at dopamine D2, D3, and D4 receptors, exhibits important neuroprotective properties independent of its dopamine receptor agonism. In cell-based assays, both RPPX and PPX reduce the production of reactive oxygen species (ROS), attenuate the activation of apoptotic pathways, and increase cell survival in response to a variety of neurotoxins. However, PPX has limited utility as a clinical neuroprotective agent because the drug concentrations required for neuroprotection would likely produce unacceptable dopaminergic side effects. RPPX, on the other hand, while possessing the same neuroprotective potential as PPX, is a much lower-affinity dopamine receptor agonist and may therefore be more useful in the treatment of ALS. This review will examine the data supporting the hypothesis that the RPPX may have therapeutic potential for the treatment of neurodegenerative disorders including ALS. In addition, we will briefly review recent preclinical data in support of RPPX, and discuss the current status of its clinical development.
Gribkoff
Valentin K
VK
Knopp Neurosciences, Inc., Pittsburgh, PA 15203, USA. valentin.gribkoff@knoppneurosciences.com
Bozik
Michael E
ME
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D052160:Benzothiazoles / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D018696:Neuroprotective Agents / Q000737:chemistry / Q000627:therapeutic use*; D000077487:Pramipexole; D013237:Stereoisomerism
D052160:Benzothiazoles; D018491:Dopamine Agonists; D018696:Neuroprotective Agents; D000077487:Pramipexole
J Neurol. 2000 Mar;247 Suppl 1:I1-6
10795881
J Neurol. 2000 Mar;247 Suppl 1:I7-16
10795882
Science. 2000 Apr 21;288(5465):399
10798964
Biochem Soc Trans. 2000 Feb;28(2):170-7
10816121
Trends Biochem Sci. 2000 Jul;25(7):319-24
10871882
Brain Res. 2000 Jul 28;872(1-2):236-41
10924701
Cell Tissue Res. 2000 Jul;301(1):173-87
10928290
Neuroreport. 2000 Aug 3;11(11):2507-9
10943712
Biochem Soc Symp. 1999;66:167-79
10989666
FEBS Lett. 2000 Sep 29;482(1-2):6-12
11018514
J Neural Transm (Vienna). 2000;107(10):1165-73
11129106
Eur J Pharmacol. 2001 Apr 6;417(1-2):59-67
11301060
J Inherit Metab Dis. 2001 Apr;24(2):166-80
11405338
Eur J Pharmacol. 2001 Jun 22;422(1-3):209-16
11430933
Horm Metab Res. 2001 Sep;33(9):511-9
11561209
Nat Rev Neurosci. 2001 Nov;2(11):806-19
11715057
Neurobiol Dis. 2001 Dec;8(6):933-41
11741389
J Neurosci Res. 2002 Feb 15;67(4):494-500
11835316
Biochimie. 2002 Feb-Mar;84(2-3):153-66
12022946
Free Radic Biol Med. 2002 Aug 1;33(3):337-49
12126755
Proc Natl Acad Sci U S A. 2002 Dec 10;99 Suppl 4:16400-6
12200548
Free Radic Biol Med. 2002 Nov 15;33(10):1314-20
12419463
Clin Genet. 2003 Feb;63(2):83-101
12630951
J Biol Inorg Chem. 2003 Apr;8(4):373-80
12644909
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3617-22
12655070
Curr Med Chem. 2003 Apr;10(8):649-61
12678784
Neurochem Res. 2003 Jul;28(7):1035-40
12737528
Curr Drug Targets CNS Neurol Disord. 2002 Oct;1(5):511-8
12769603
Eur J Pharmacol. 2003 Aug 15;475(1-3):29-35
12954356
Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):136-43
13129799
Anesth Analg. 2003 Oct;97(4):1020-4, table of contents
14500151
J Physiol. 2003 Oct 15;552(Pt 2):335-44
14561818
Neuropathol Appl Neurobiol. 2003 Dec;29(6):529-45
14636160
Neurologist. 2004 Jan;10(1):1-7
14720310
Biomed Pharmacother. 2004 Jan;58(1):39-46
14739060
Ann Neurol. 2004 Mar;55(3):306-19
14991808
FASEB J. 2004 May;18(7):869-71
15033929
Neuroscience. 2004;125(1):191-201
15051158
Eur J Med Chem. 2004 Mar;39(3):291-8
15051178
Annu Rev Neurosci. 2004;27:723-49
15217349
Free Radic Biol Med. 2004 Sep 15;37(6):755-67
15304252
J Bioenerg Biomembr. 2004 Aug;36(4):395-9
15377878
Annu Rev Cell Dev Biol. 2004;20:309-35
15473843
J Neurochem. 2004 Dec;91(5):1075-81
15569251
J Neurosci Res. 2005 Jan 1-15;79(1-2):231-9
15573402
Neurochem Res. 2004 Nov;29(11):1943-9
15662830
J Biol Chem. 2005 Apr 29;280(17):17266-74
15691826
Protein Sci. 2005 May;14(5):1201-13
15840828
J Neurol Sci. 2005 Jun 15;233(1-2):145-62
15896810
Arch Immunol Ther Exp (Warsz). 2005 May-Jun;53(3):213-25
15995582
J Neurosci. 2005 Jul 6;25(27):6449-59
16000635
Neurobiol Dis. 2006 Jan;21(1):228-36
16111888
Antioxid Redox Signal. 2005 Sep-Oct;7(9-10):1140-9
16115017
Exp Neurol. 2006 Mar;198(1):25-30
16126198
Trends Genet. 2005 Nov;21(11):583-6
16154228
J Pharmacol Exp Ther. 2006 Jan;316(1):189-99
16188953
Nat Rev Genet. 2005 Nov;6(11):815-25
16304597
Naunyn Schmiedebergs Arch Pharmacol. 2006 Jan;372(4):257-66
16362428
FASEB J. 2006 Mar;20(3):556-8
16407457
Biochim Biophys Acta. 2006 Feb;1757(2):79-89
16473322
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7142-7
16636275
FEBS J. 2006 May;273(10):2077-99
16649987
Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):1013-24
16675207
Biochim Biophys Acta. 2006 May-Jun;1763(5-6):542-8
16730811
Antioxid Redox Signal. 2006 May-Jun;8(5-6):847-67
16771675
Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):1025-37
16814528
Curr Biol. 2006 Jul 25;16(14):R551-60
16860735
Neurodegener Dis. 2004;1(6):245-54
16908975
Neuron. 2006 Oct 5;52(1):39-59
17015226
Curr Alzheimer Res. 2006 Sep;3(4):339-49
17017864
Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):1150-7
17071060
Biochem Biophys Res Commun. 2006 Dec 22;351(3):602-11
17084815
Mol Membr Biol. 2006 Nov-Dec;23(6):521-30
17127624
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001447
17253460
Neuroscience. 2007 Apr 14;145(4):1233-48
17303344
Acta Neuropathol. 2007 May;113(5):535-42
17333220
Cell Death Differ. 2007 Jul;14(7):1261-6
17464321
Cell Death Differ. 2007 Aug;14(8):1529-41
17464322
Ann Neurol. 2007 May;61(5):427-34
17469116
Curr Opin Neurobiol. 2007 Jun;17(3):331-7
17499497
J Biol Inorg Chem. 2007 Aug;12(6):797-807
17530304
Acta Neuropathol. 2007 Jul;114(1):71-9
17569066
Cell Physiol Biochem. 2007;20(1-4):1-22
17595511
Curr Opin Investig Drugs. 2007 Jul;8(7):555-62
17659475
Am J Alzheimers Dis Other Demen. 2007 Aug-Sep;22(4):300-12
17712161
J Neurosci. 2007 Dec 19;27(51):13997-4006
18094238
Amyotroph Lateral Scler. 2008 Feb;9(1):50-8
18270879
Science. 2008 Mar 21;319(5870):1668-72
18309045
Lancet Neurol. 2008 May;7(5):409-16
18396105
Rev Neurol (Paris). 1991;147(6-7):417-30
1962047
J Med Chem. 1987 Mar;30(3):494-8
3820220
J Neuropathol Exp Neurol. 1985 Jul;44(4):430-8
4040157
J Neuropathol Exp Neurol. 1984 Sep;43(5):471-80
6540800
Eur J Pharmacol. 1995 Apr 24;277(2-3):209-14
7493610
Neuron. 1995 Jun;14(6):1105-16
7605627
Eur J Pharmacol. 1995 Jun 23;290(1):29-36
7664822
J Biol Chem. 1995 Feb 17;270(7):3234-8
7852409
J Bioenerg Biomembr. 1994 Oct;26(5):509-17
7896766
Hum Mol Genet. 1994 Jun;3(6):981-7
7951249
Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8292-6
8058797
Mol Pharmacol. 1994 May;45(5):1055-60
8190096
Ger J Ophthalmol. 1995 Nov;4(6):355-62
8751101
Neurol Clin. 1996 May;14(2):399-420
8827179
Neurology. 1996 Oct;47(4 Suppl 2):S54-61; discussion S61-2
8858052
Neurology. 1996 Oct;47(4 Suppl 2):S71-81; discussion S81-2
8858055
Neuropathol Appl Neurobiol. 1996 Oct;22(5):373-87
8930947
Neurology. 1996 Dec;47(6 Suppl 4):S233-41
8959995
Brain Res. 1996 Dec 2;742(1-2):80-8
9117424
Brain Res. 1997 Apr 18;754(1-2):181-6
9134974
Brain Res. 1997 May 9;756(1-2):247-55
9187339
J Pharmacol Exp Ther. 1997 Aug;282(2):707-14
9262334
J Pharmacol Exp Ther. 1997 Sep;282(3):1280-90
9316836
Arch Neurol. 1997 Oct;54(10):1246-50
9341570
Semin Neurol. 1998;18(1):27-39
9562665
J Neurochem. 1998 Jul;71(1):295-301
9648878
Biochim Biophys Acta. 1998 Aug 10;1366(1-2):139-49
9714780
Science. 1998 Sep 18;281(5384):1851-4
9743498
Exp Neurol. 1998 Sep;153(1):135-42
9743575
Ultrastruct Pathol. 1998 Sep-Oct;22(5):357-67
9887478